



Health Alert Network

Tri-County Health Department

Serving Adams, Arapahoe and Douglas Counties

Phone 303/220-9200 • Fax 303/741-4173 • www.tchd.org

Follow us on Twitter @TCHDHealth

John M. Douglas, Jr., M.D. Executive Director

The pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.

HAN UPDATE

Number of pages including cover: 7

Subject: **Update - COVID-19 Paxlovid Patient Eligibility Screening Checklist – May 11, 2022**

Message ID: 5/11/2022 11:45:00 AM

Recipients: HAN Community Members.

From: TRI-COUNTY HEALTH DEPARTMENT

Adams, Arapahoe and Douglas County, Colorado

Recipient Instructions: **Health care providers: Please distribute widely in your office.**

For more information:

- TCHD COVID-19 Vaccine web page: <https://www.tchd.org/866/COVID-19-Vaccines>
- TCHD COVID-19 web page: <http://www.tchd.org/818/Coronavirus-COVID-19>
- Information on free COVID-19 testing locations: <https://www.tchd.org/827/Free-COVID-19-Testing-Sites>
- CDPHE COVID-19 web page: <https://covid19.colorado.gov/>
- CDC COVID-19 web page: <https://www.cdc.gov/coronavirus/2019-ncov/index.html>
- For questions about COVID-19 please call Tri-County Health Department at 303-220-9200
- Members of the public may contact CO Help at 303-389-1687 or 1-877-462-2911 with general questions about COVID-19 to receive answers in many languages including English, Spanish (Español), Mandarin (普通话), and more, or email COHELP@RMPDC.org (for answers in English only).

You have received this message based upon the information contained within our Health Alert Network Notification System. If you have a different or additional e-mail or fax address that you would like us to use, or if you have additional questions, call 720-200-1477.

Categories of Health Alert Network Messages:

Health Alert: Conveys the highest level of importance; warrants immediate action or attention.

Health Advisory: Provides important information for a specific incident or situation; may not require immediate action.

Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate action.

Info Service/Public Health Brief: Provides general information that is not necessarily considered to be of an emergent nature.

You may download a copy of this HAN from the TCHD website at <http://www.tchd.org/259/Health-Alert-Network>



May 11, 2022

On April 8, 2022, CDPHE released a HAN summarizing current recommendations for COVID-19 therapeutics. Over the past month, federal agencies have continued to secure a substantial number of treatment doses available to all states and CDPHE has reported having ample supply of medications for our residents at this time.

TCHD strongly encourages providers to set up processes to rapidly (i.e., same day in-person or virtual visit) assess the risk of COVID-19 complications in outpatients who report a positive test or are likely to have COVID-19 illness. For persons at higher risk, initiating treatment within 5 days of illness onset is ideal.

FDA recently released a helpful checklist to assist provider decision-making for prescribing Paxlovid and streamline your clinical evaluation:

FDA's Paxlovid Patient Eligibility Screening Checklist

<https://www.fda.gov/media/158165/download>

Here is a list of additional resources on Paxlovid and COVID-19 therapeutics:

University of Liverpool Reference for determining COVID-19 Drug Interactions

<https://www.covid19-druginteractions.org/checker>

COVID-19 Test to Treat Locator Tool (clinics offering testing and treatment onsite)

<https://aspr.hhs.gov/TestToTreat/Pages/default.aspx>

COVID-19 Therapeutics Locator (list of pharmacies that carry Paxlovid and other therapeutics)

<https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>

FDA's Paxlovid Fact Sheet for Providers

<https://www.fda.gov/media/155050/download>

FDA Q&A on use of Paxlovid for eligible patients

<https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers>

CDC general information on COVID-19 Therapeutics

<https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html>

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

This checklist is intended as an aid to support clinical decision making for prescribers. However, use of this checklist is not required to prescribe PAXLOVID under the EUA.

Medical History

- Positive SARS-CoV-2 test (Confirmation of a positive home rapid SARS-CoV-2 test result with additional direct SARS-CoV-2 viral testing is not required.)
- Age \geq 18 years OR \geq 12 years of age and weighing at least 40 kg
- Has one or more risk factors for progression to severe COVID-19¹ (Risk factors have changed over time, and additional risk factors [such as being unvaccinated or having not received a booster] could be considered. Healthcare providers should consider the benefit-risk for an individual patient.)
- Symptoms consistent with mild to moderate COVID-19²
- Symptom onset within 5 days (Prescriber is encouraged to include a note to the pharmacist in the prescription stating: Please fill prescription by [insert date]. This prescription fill by date is within 5 days from symptom onset and complies with the patient eligibility criteria under the EUA.)
- Not requiring hospitalization due to severe or critical COVID-19 at treatment initiation
- No known or suspected severe renal impairment (eGFR \leq 30 mL/min)
 - Note that a dose reduction is required for patients with moderate renal impairment (eGFR \geq 30-<60 mL/min); see the Fact Sheet for Healthcare Providers.
 - Prescriber may rely on patient history and access to the patient's health records to make an assessment regarding the likelihood of renal impairment. Providers may consider ordering a serum creatinine or calculating the estimated glomerular filtration rate (eGFR) for certain patients after assessment on a case-by-case basis based on history or exam.
- No known or suspected severe hepatic impairment (Child-Pugh Class C)
- No history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product

NOTES: _____

¹ <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>.

² <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/#:~:text=Patients%20with%20mild%20illness%20may,on%20exertion%2C%20or%20abnormal%20imaging>

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Concomitant Medications

HMG-CoA reductase inhibitors (statins)

- *Patient is taking lovastatin or simvastatin*, which are contraindicated with PAXLOVID coadministration: The statin can be held 12 hours prior to the first dose of PAXLOVID treatment, held during the 5 days of treatment, and restarted 5 days after completing PAXLOVID.
- *Patient is taking atorvastatin or rosuvastatin*: Temporary discontinuation of atorvastatin and rosuvastatin during treatment with PAXLOVID should be considered depending on statin dose. Atorvastatin and rosuvastatin do not need to be held prior to or after completing PAXLOVID.

NOTES: _____

Hormonal contraceptives containing ethinyl estradiol: *Patient is taking a hormonal contraceptive containing ethinyl estradiol*: The need for an additional non-hormonal method of contraception during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID should be recommended.

NOTES: _____

Medications for HIV-1 Treatment: *Patient is taking medications for the treatment of HIV-1 infection*: With the exception of maraviroc³, HIV antiretroviral medications can be co-administered with PAXLOVID without dose adjustment, but arranging follow-up by the HIV care provider to monitor for side effects is recommended^{4,5,6}.

NOTES: _____

Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID

- Patient is not taking any of the medications listed below.
- Patient is taking one or more of the medications listed below in YELLOW, and dose adjustment, holding of medication, or increased monitoring is planned (additional resources which include instructions for managing specific drug interactions are included at the end of this document).

NOTES: _____

³ Please see the maraviroc prescribing information here:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022128Orig1s019,208984Orig1s002lbl.pdf

⁴ Exposure of certain HIV medications may be altered with PAXLOVID co-administration.

⁵ Patients on ritonavir- or cobicistat-containing HIV or HCV regimens should continue their treatment as indicated.

⁶ PAXLOVID use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID (listed alphabetically by generic name)

Interaction Codes:



Coadministration of this drug with PAXLOVID is CONTRAINDICATED. For further information, refer to the Fact Sheet for Healthcare Providers and the individual Prescribing Information for the drug.



Coadministration of this drug with PAXLOVID should be avoided and/or holding of this drug, dose adjustment of this drug, or special monitoring is necessary. Consultation with the prescriber of the potentially interacting drug is recommended. For further information, refer to the Health Care Provider Fact Sheet and the individual Prescribing Information for the drug.

Drug	Drug Class	Interaction Code
abemaciclib	Anticancer drug	***
alfuzosin	Alpha 1-adrenoreceptor antagonist	XXX
amiodarone	Antiarrhythmic	XXX
amlodipine	Calcium channel blocker	***
apalutamide	Anticancer drug	XXX
bedaquiline	Antimycobacterial	***
bepidil	Antiarrhythmic	***
betamethasone	Systemic corticosteroid	***
bosentan	Endothelin receptor antagonist	***
budesonide	Systemic corticosteroid	***
bupropion	Antidepressant	***
carbamazepine	Anticonvulsant	XXX
ceritinib	Anticancer drug	***
ciclesonide	Systemic corticosteroid	***
clarithromycin	Anti-infective	***
clozapine	Antipsychotic	XXX
colchicine	Anti-gout	XXX
cyclosporine	Immunosuppressant	***
dabigatran	Anticoagulants	***
dasabuvir	Hepatitis C direct acting antiviral	***
dasatinib	Anticancer drug	***
dexamethasone	Systemic corticosteroid	***

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Drug	Drug Class	Interaction Code
digoxin	Cardiac glycoside	***
dihydroergotamine	Ergot derivative	XXX
diltiazem	Calcium channel blocker	***
dronedarone	Antiarrhythmic	XXX
elbasvir/grazoprevir	Hepatitis C direct acting antiviral	***
encorafenib	Anticancer drug	***
ergotamine	Ergot derivative	XXX
erythromycin	Anti-infective	***
felodipine	Calcium channel blocker	***
fentanyl	Narcotic analgesic	***
flecainide	Antiarrhythmic	XXX
fluticasone	Systemic corticosteroid	***
glecaprevir/pibrentasvir	Hepatitis C direct acting antiviral	***
ibrutinib	Anticancer drug	***
isavuconazonium sulfate	Antifungal	***
itraconazole	Antifungal	***
ivosidenib	Anticancer drug	***
ketoconazole	Antifungal	***
lidocaine (systemic)	Antiarrhythmic	***
lurasidone	Antipsychotic	XXX
methadone	Narcotic analgesic	***
methylergonovine	Ergot derivative	XXX
methylprednisolone	Systemic corticosteroid	***
midazolam (administered parentally)	Sedative/hypnotic	***
midazolam (oral)	Sedative/hypnotic	XXX
mometasone	Systemic corticosteroid	***
neratinib	Anticancer drug	***
nicardipine	Calcium channel blocker	***
nifedipine	Calcium channel blocker	***
nilotinib	Anticancer drug	***
ombitasvir/paritaprevir /ritonavir	Hepatitis C direct acting antiviral	***
pethidine	Analgesic	XXX
phenobarbital	Anticonvulsant	XXX
phenytoin	Anticonvulsant	XXX
pimozide	Antipsychotic	XXX
prednisone	Systemic corticosteroid	***
propafenone	Antiarrhythmic	XXX
propoxyphene	Analgesic	XXX
quetiapine	Antipsychotic	***
quinidine	Antiarrhythmic	XXX
ranolazine	Antianginal	XXX

PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Drug	Drug Class	Interaction Code
rifabutin	Antimycobacterial	***
rifampin	Antimycobacterial	XXX
rivaroxaban	Anticoagulant	***
salmeterol	Long-acting beta-adrenoceptor agonist	***
sildenafil (Revatio®) when used for pulmonary arterial hypertension	PDE5 inhibitor	XXX
sirolimus	Immunosuppressant	***
sofosbuvir/velpatasvir/ voxilaprevir	Hepatitis C direct acting antiviral	***
St. John's Wort (hypericum perforatum)	Herbal product	XXX
tacrolimus	Immunosuppressant	***
trazodone	Antidepressant	***
triamcinolone	Systemic corticosteroid	***
triazolam	Sedative/hypnotic	XXX
venetoclax	Anticancer drug	***
vinblastine	Anticancer drug	***
vincristine	Anticancer drug	***
voriconazole	Antifungal	***
warfarin	Anticoagulant	***

ADDITIONAL RESOURCES:

PAXLOVID - Fact Sheet for Healthcare Providers: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs>

Prescribing Information (Label/Package Insert) for Individual Drugs (Drugs@FDA): <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>

University of Liverpool COVID-19 Drug Interactions: <https://www.covid19-druginteractions.org/checker>

NIH COVID-19 Treatment Guidelines: <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid/>